Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
Vavricka SR, Spasojevic M, Rogler G, Schoepfer AM, Seibold F, Borovicka J, Frei P, Zeitz J, Greuter T, Manser C, Scharl M, Misselwitz B, Straumann A, Michetti P, Biedermann L; Swiss IBDnet.
Vavricka SR, et al. Among authors: seibold f.
Dig Dis. 2017;35(5):423-432. doi: 10.1159/000475494. Epub 2017 Jun 9.
Dig Dis. 2017.
PMID: 28595194
Free article.